Vanguard Group’s Urovant Sciences Ltd. UROV Stock Holding History

Vanguard Group’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-341,426	Closed	-$5.51M	–	4344
2020 Q4	$5.51M	Buy	341,426 +209,939	+160%	+$2.6M	﹤0.01%	3320
2020 Q3	$1.23M	Hold	131,487	–	–	﹤0.01%	3610
2020 Q2	$1.29M	Hold	131,487	–	–	﹤0.01%	3546
2020 Q1	$1.21M	Hold	131,487	–	–	﹤0.01%	3441
2019 Q4	$2.04M	Hold	131,487	–	–	﹤0.01%	3442
2019 Q3	$1.25M	Hold	131,487	–	–	﹤0.01%	3589
2019 Q2	$1.04M	Buy	131,487 +9,000	+7%	+$73.8K	﹤0.01%	3666
2019 Q1	$1.23M	Buy	122,487 +30,163	+33%	+$309K	﹤0.01%	3572
2018 Q4	$608K	Buy	+92,324	New	+$840K	﹤0.01%	3687

Vanguard Group's UROV Position: Q1 2021 in Review

Vanguard Group sold out of Urovant Sciences Ltd. (UROV) in Q1 2021, closing a stake of 341,426 shares — an estimated $5.51M sold.

Vanguard Group first reported a position in UROV in Q4 2018 and held it in 9 quarters. The position peaked at $5.51M in Q4 2020. 0 funds tracked by Wall St. Rank hold UROV as of Q1 2021.

Vanguard Group reported no remaining Urovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
Vanguard Group sold 341,426 Urovant Sciences Ltd. shares in Q1 2021, an estimated $5.51M.
Vanguard Group first reported a position in Urovant Sciences Ltd. in Q4 2018 and held it in 9 quarters.
Vanguard Group's Urovant Sciences Ltd. position peaked at $5.51M in Q4 2020.
0 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2021.

Based on Vanguard Group's 13F filing for Q1 2021, filed 14 May 2021.